MedTrace Logo

CC-223 and Ketoconazole Drug-Drug Interaction Study

NCT01896323 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-11-12

No results posted yet for this study

Summary

This is a single-center open-label study to compare how CC-223 (the study drug being investigated) interacts with the drug ketoconazole.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CC-223

CC-223 20 mg tablets

DRUG

Ketoconazole

Ketoconazole 400 mg tablets

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Edward O'Mara, MD · Celgene Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-01
Primary Completion
2013-08-01
Completion
2013-08-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01896323 on ClinicalTrials.gov